1228312-13-7 Usage
General Description
The chemical (R)-2-(1-(tert-butoxycarbonyl)pyrrolidin-3-yl)malonic acid is a compound with a molecular structure consisting of a pyrrolidinyl group attached to a malonic acid moiety. It is commonly used as an intermediate in organic synthesis for the preparation of various pharmaceuticals and agrochemicals. The tert-butoxycarbonyl (Boc) protective group in the compound ensures the stability of the pyrrolidine moiety during synthetic processes. This chemical has potential applications in the pharmaceutical industry for the development of new drug compounds due to its versatile reactivity and functional groups. Additionally, it is used in research and development for the introduction of pyrrolidine into organic molecules for structure-activity relationship studies and drug discovery.
Check Digit Verification of cas no
The CAS Registry Mumber 1228312-13-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,2,8,3,1 and 2 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1228312-13:
(9*1)+(8*2)+(7*2)+(6*8)+(5*3)+(4*1)+(3*2)+(2*1)+(1*3)=117
117 % 10 = 7
So 1228312-13-7 is a valid CAS Registry Number.
1228312-13-7Relevant articles and documents
BIARYL DERIVATIVE AS GPR120 AGONIST
-
, (2017/11/17)
The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a GPR120 agonist, promoting GLP-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.
SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-(PYRROLIDIN-3-YLVINYL)PYRIMIDINE
-
Page/Page column 35, (2010/06/20)
The present invention relates to the stereospecific synthesis of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, its salt forms, and novel polymorphic forms of these salts.
